ArticleJournal of affective disorders2026
Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample.
Article in Journal of affective disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.Npj mental health research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ketamine is known to be a rapid-acting antidepressant, but there is limited evidence regarding which types of patients are best-suited to this treatment and whether adjunctive psychotherapy improves outcomes. In a sample of 224 patients who received five ketamine infusions at a private clinic, this study uses Bayesian mixed modeling to examine the effects of early life stress (measured with the Adverse Childhood Experiences [ACE] survey) and treatment modality (ketamine-assisted therapy [KAT] vs. infusions only) on antidepressant response, and whether these effects interact. Depression symptoms were assessed prior to each infusion using the Patient Health Questionnaire-9 survey. Depression symptoms improved over time (time: β = -4.4, 95% Credible Interval [-6.8, -1.9]), with decelerating rates of improvement (quadratic time: β = 2.6, [0.4, 4.8]). Symptom trajectories did not differ between treatment modalities (time*treatment condition: β = 0.8, [-1.6, 3.1]). Higher ACE scores were associated with greater symptom reduction (time*ACE: β = -0.6, [-0.9, -0.3]), independent of treatment modality (time*ACE*treatment condition: β = -0.5, [-1.1, 0.2]). Exploratory analyses revealed that younger adults show greater treatment response to ketamine infusions alone compared to KAT, while the opposite is observed in older adults (time*treatment condition*age: β = -0.1, [-0.3, -0.03]). Furthermore, the relationship between higher ACE scores and greater symptom reduction may be particularly strong within younger adults, with this association reversing at older ages (time*ACE*age: β = 0.02, [0.002, 0.04]). In summary, enhanced magnitude of symptom reduction for those with greater early life stress exposure, especially in younger adults, suggests a potentially unique and targeted benefit of ketamine over conventional antidepressants for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.